GlassScriptPhysician profile
Robert C Mcmyne
NPI 1588825160
$4,589.29
in general payments reported to CMS, 2019-2025
31 companies · $892 in 2025
The $892 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $222 · 2021: $694 · 2022: $673 · 2023: $1,093 · 2024: $544 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,132 · Travel and Lodging: $397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,132.10 |
| Travel and Lodging | $397.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,154.96 | 2021-2025 | |
| Stryker Corporation | $730.36 | 2019-2025 | Mild Device Kit, Spinejack, Avaflex |
| Boston Scientific Corporation | $610.99 | 2020-2025 | Clinical Trial Product, Wavewriter Alpha Prime 16 |
| Pfizer INC. | $348.39 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $208.63 | 2022 | |
| Spr Therapeutics, INC | $186.37 | 2023-2024 | Sprint Pns System |
| Biohaven Pharmaceuticals, INC. | $160.65 | 2021 | |
| Medtronic, INC. | $99.91 | 2021-2023 | Kyphon Express II Kyphopak Tray |
| Azurity Pharmaceuticals, INC. | $98.54 | 2023-2024 | Horizant, Horizant |
| Arbor Pharmaceuticals, INC. | $89.56 | 2019-2021 | |
| Abbott Laboratories | $86.64 | 2019-2021 | |
| Amgen INC. | $78.66 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $78.21 | 2019 | |
| Zyla Life Sciences, INC. | $71.46 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $60.77 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $52.73 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $52.16 | 2019-2020 | |
| Radius Health, INC. | $48.50 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $48.33 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.40 | 2023-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $40.55 | 2023-2024 | Belbuca |
| Medtronic USA, INC. | $39.86 | 2019-2020 | |
| Allergan, INC. | $34.94 | 2020 | |
| Lundbeck LLC | $29.45 | 2024 | Vyepti |
| Biotronik Nro, INC. | $29.36 | 2025 | Prospera |
| Averitas Pharma INC. | $24.31 | 2023 | Qutenza |
| Ibsa Pharma INC. | $24.29 | 2022 | |
| Nalu Medical, INC. | $22.14 | 2024 | Nalu Neurostimulation System |
| Avanos Medical | $17.01 | 2025 | Coolief Cooled Radiofrequency |
| Daiichi Sankyo INC. | $11.47 | 2019 | |
| Vertos Medical, INC. | $6.69 | 2024 | Mild Device Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mcmyne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.